<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419562</url>
  </required_header>
  <id_info>
    <org_study_id>TN07 Oral Insulin</org_study_id>
    <secondary_id>UC4DK106993</secondary_id>
    <secondary_id>UC4DK117009</secondary_id>
    <nct_id>NCT00419562</nct_id>
  </id_info>
  <brief_title>Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus</brief_title>
  <acronym>TN07</acronym>
  <official_title>Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>American Diabetes Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes (T1D) is an autoimmune disease. This means that the immune system (the part
      of the body which helps fight infections) mistakenly attacks and destroys the cells that
      produce insulin (islet cells found in the pancreas). As these cells are destroyed, the body's
      ability to produce insulin decreases. There is evidence suggesting that repeated oral
      administration of an autoantigen (the same protein that the immune system is reacting to) may
      introduce a protective immunity and cause the immune system to stop its attack. An earlier,
      large scale study was done to see if oral insulin could delay or prevent the development of
      Type 1 diabetes in relatives at risk for developing Type 1 diabetes. The overall results
      showed that for the entire study population, oral insulin did not delay or prevent Type 1
      diabetes. However, an analysis that was done after the conclusion of the trial suggested a
      potential beneficial effect in a subgroup of participants. The participants who seemed to
      benefit from oral insulin had higher levels of insulin autoantibodies which are directed
      against insulin itself ( called mIAA).

      The Type 1 Diabetes TrialNet study group will further explore the potential role of oral
      insulin to delay or prevent Type 1 diabetes in a similar group of people. The study will also
      include a secondary group of individuals at different levels of risk than those in the
      primary cohort to gather information for future studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible participants will be randomized to receive either oral insulin (7.5 mg of
      recombinant human insulin crystals) or placebo daily.

      All participants randomized into this study will be seen at a study site for a follow-up
      evaluation, three and six months after randomization, and every six months thereafter.
      Participants will be contacted by phone between 6-monthly clinic visits to assess changes in
      diabetes status, medication compliance and adverse events. These phone contacts will occur
      approximately 3 months from the date of the participants previous clinic visit.

      At the study visits, participants will undergo assessments of their insulin production,
      immunologic status, and overall health. As the primary outcome measure, subjects will be
      followed until development of type 1 diabetes or the conclusion of the study. The trial is
      expected to last approximately 7-8 years or until the required amount of information is
      gathered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo</measure>
    <time_frame>Metabolic and immunological tests were conducted every 6 months; participants were followed for a median of 2.7 years</time_frame>
    <description>Primary outcome is reported as the rate of type 1 diabetes per year among the primary stratum; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Type 1 Diabetes Per Year in Secondary Stratum (Stratum 2) When Treated With Oral Insulin Versus Placebo</measure>
    <time_frame>Metabolic and immunological tests were conducted every 6 months; participants were followed for a median of 2.7 years</time_frame>
    <description>Secondary outcome is reported as the rate of type 1 diabetes per year among secondary stratum 2; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Type 1 Diabetes in Secondary Stratum (Stratum 3+4) When Treated With Oral Insulin Versus Placebo</measure>
    <time_frame>Metabolic and immunological tests were conducted every 6 months; participants were followed for a median of 2.7 years</time_frame>
    <description>Secondary outcome is reported as the rate of type 1 diabetes per year among secondary stratum 3+4; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">560</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>Oral Insulin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7.5 mg oral insulin capsules given before breakfast on a daily basis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule designed to match appearance of treatment capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Insulin</intervention_name>
    <description>7.5 mg oral insulin or placebo given before breakfast on a daily basis.</description>
    <arm_group_label>Oral Insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule designed to match active drug</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have a proband with Type 1 diabetes mellitus (T1DM). A proband is an individual
             diagnosed with diabetes before age 40 and started on insulin therapy within 1-year of
             diagnosis. Probands considered to have type 1 diabetes by their physician who do not
             meet this definition will be referred to the TrialNet Eligibility Committee.

          2. If the proband is a parent, sibling or a child, the study participant must be 3 -45
             years of age. If the proband is a second or third degree relative (i.e. niece, nephew,
             aunt, uncle, grandparent, cousin, or half-sibling), the study participant must be 3-20
             years of age.

          3. Willing to sign Informed Consent Form.

          4. Oral glucose tolerance test (OGTT) performed within 7 weeks prior to randomization in
             which:

               -  fasting plasma glucose &lt; 110 mg/dL (6.1 mmol/l), and

               -  2 hour plasma glucose &lt; 140 mg/dL (7.8 mmol/l)

          5. mIAA confirmed positive within the previous six months.

          6. Two samples with at least one autoantibody other than mIAA positive within the
             previous six months.

        Exclusion Criteria:

          1. Does not satisfy the above inclusion criteria. Subjects with mIAA positive but no
             other autoantibodies positive are not eligible for randomization.

          2. Has severe active disease, e.g. chronic active hepatitis, severe cardiac, pulmonary,
             renal, hepatic, immune deficiency and/or disease that is likely to limit life
             expectancy or lead to therapies such as immunosuppression during the time of the
             study.

          3. Prior participation in a trial for prevention of T1DM, e.g. nicotinamide, insulin,
             immunosuppressive drugs.

          4. History of treatment with insulin or oral hypoglycemic agent.

          5. History of therapy with immunosuppressive drugs or glucocorticoids within the past two
             years for a period of more than three months.

          6. Ongoing use of medications known to influence glucose, i.e. sulfonylureas, growth
             hormone, metformin, anticonvulsants, thiazide or potassium depleting diuretics, beta
             adrenergic blockers, niacin. Subjects on such medications should be changed to a
             suitable alternative, if available, and will become eligible one month after
             medication is discontinued.

          7. Pregnant or intends to become pregnant while on study or lactating.

          8. Deemed unlikely or unable to comply with the protocol.

          9. OGTT that reveals Diabetes, Impaired Glucose Tolerance (IGT), or Impaired Fasting
             Glucose (IFG).

             Diabetes is defined by:

               -  fasting plasma glucose ³ 126 mg/dL (7 mmol/l), OR

               -  2 hour plasma glucose ³ 200 mg/dL (11.1 mmol/l)

             IGT is defined by:

               -  fasting plasma glucose &lt; 126 mg/dL (7 mmol/l), and

               -  2 hour plasma glucose 140-199 mg/dL (7.8 - 11mmol/l),

             IFG is defined by:

               -  fasting plasma glucose 110-125 mg/dL (6.1-6.9 mmol/l) AND

               -  2 hour plasma glucose &lt; 140 mg/dL (7.8 mmol/l)

         10. Subject has HLA DQA1*0102, DQB1*0602 haplotype.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carla J Greenbaum, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Benaroya Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeff Krischer, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of South Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California-San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610-0296</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University-Riley Hospital for Children</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Childrens Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Eskind Diabetes Clinic</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235-8858</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Benaroya Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Walter and Eliza Hall Institute</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Turku</name>
      <address>
        <city>Turku</city>
        <zip>FIN-20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>Milan</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS10 5NB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Finland</country>
    <country>Italy</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://www.diabetestrialnet.org</url>
    <description>Type 1 Diabetes TrialNet</description>
  </link>
  <link>
    <url>http://www.diabetes.org</url>
    <description>American Diabetes Association</description>
  </link>
  <link>
    <url>http://www.jdrf.org</url>
    <description>Juvenile Diabetes Foundation International</description>
  </link>
  <reference>
    <citation>Bergerot I, Fabien N, Maguer V, Thivolet C. Oral administration of human insulin to NOD mice generates CD4+ T cells that suppress adoptive transfer of diabetes. J Autoimmun. 1994 Oct;7(5):655-63.</citation>
    <PMID>7840857</PMID>
  </reference>
  <reference>
    <citation>Muir A, Schatz D, Maclaren N. Antigen-specific immunotherapy: oral tolerance and subcutaneous immunization in the treatment of insulin-dependent diabetes. Diabetes Metab Rev. 1993 Dec;9(4):279-87. Review.</citation>
    <PMID>7924825</PMID>
  </reference>
  <reference>
    <citation>Muir A, Peck A, Clare-Salzler M, Song YH, Cornelius J, Luchetta R, Krischer J, Maclaren N. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislet interferon-gamma transcription. J Clin Invest. 1995 Feb;95(2):628-34.</citation>
    <PMID>7860747</PMID>
  </reference>
  <reference>
    <citation>Zhang ZJ, Davidson L, Eisenbarth G, Weiner HL. Suppression of diabetes in nonobese diabetic mice by oral administration of porcine insulin. Proc Natl Acad Sci U S A. 1991 Nov 15;88(22):10252-6.</citation>
    <PMID>1946445</PMID>
  </reference>
  <reference>
    <citation>Skyler JS, Krischer JP, Wolfsdorf J, Cowie C, Palmer JP, Greenbaum C, Cuthbertson D, Rafkin-Mervis LE, Chase HP, Leschek E. Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1. Diabetes Care. 2005 May;28(5):1068-76.</citation>
    <PMID>15855569</PMID>
  </reference>
  <reference>
    <citation>Lachin JM. Maximum information designs. Clin Trials. 2005;2(5):453-64.</citation>
    <PMID>16315649</PMID>
  </reference>
  <results_reference>
    <citation>Writing Committee for the Type 1 Diabetes TrialNet Oral Insulin Study Group, Krischer JP, Schatz DA, Bundy B, Skyler JS, Greenbaum CJ. Effect of Oral Insulin on Prevention of Diabetes in Relatives of Patients With Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2017 Nov 21;318(19):1891-1902. doi: 10.1001/jama.2017.17070.</citation>
    <PMID>29164254</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 4, 2007</study_first_submitted>
  <study_first_submitted_qc>January 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 8, 2007</study_first_posted>
  <results_first_submitted>January 4, 2018</results_first_submitted>
  <results_first_submitted_qc>February 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2020</results_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral insulin</keyword>
  <keyword>autoantigen</keyword>
  <keyword>self tolerance</keyword>
  <keyword>oral tolerance</keyword>
  <keyword>Diabetes Prevention Trial - 1 (DPT-1)</keyword>
  <keyword>prevention</keyword>
  <keyword>&quot;at risk&quot; for developing type 1 diabetes</keyword>
  <keyword>juvenile diabetes</keyword>
  <keyword>Type 1 diabetes (T1D)</keyword>
  <keyword>diabetes mellitus</keyword>
  <keyword>Type 1 diabetes TrialNet</keyword>
  <keyword>TrialNet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data are available at the NIDDK Central Repository: https://repository.niddk.nih.gov/studies/tn07-oral-insulin/?query=tn07</ipd_description>
    <ipd_url>https://repository.niddk.nih.gov/studies/tn07-oral-insulin/?query=tn07</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>7.5 mg Oral Insulin Capsules</title>
          <description>given before breakfast on a daily basis.</description>
        </group>
        <group group_id="P2">
          <title>Placebo Capsule</title>
          <description>designed to mimic appearance of treatment capsule</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="283"/>
                <participants group_id="P2" count="277"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="250"/>
                <participants group_id="P2" count="246"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Institutionalized</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Insulin</title>
          <description>7.5 mg oral insulin capsules given before breakfast on a daily basis.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo capsule designed to mimic appearance of treatment capsule</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="283"/>
            <count group_id="B2" value="277"/>
            <count group_id="B3" value="560"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" lower_limit="5.9" upper_limit="12.5"/>
                    <measurement group_id="B2" value="8.2" lower_limit="5.4" upper_limit="11.5"/>
                    <measurement group_id="B3" value="8.2" lower_limit="5.7" upper_limit="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="220"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="170"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="256"/>
                    <measurement group_id="B2" value="252"/>
                    <measurement group_id="B3" value="508"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race was collected based on self-report</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Self-Reported Race</title>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="252"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="501"/>
                  </measurement_list>
                </category>
                <category>
                  <title>African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian/Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="226"/>
                    <measurement group_id="B2" value="227"/>
                    <measurement group_id="B3" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>New Zealand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stratum</title>
          <description>4 stratum defined by autoantibodies &amp; beta cell functioning; autoantibodies include: microinsulin autoantibody (mIAA), islet cell autoantibodies (ICA), insulinoma associated antigen-2 (ICA512), &amp; glutamic acid decarboxylase (GAD65)
Positive for mIAA &amp; positive for either ICA or ICA512 &amp; GAD65; high functioning beta cells (primary)
Positive for mIAA &amp; positive for either ICA or ICA512 &amp; GAD65; low functioning beta cells
Positive for mIAA &amp; positive for ICA512 or GAD65; high functioning beta cells
Positive for mIAA &amp; positive for ICA512 or GAD65; low functioning beta cells</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="186"/>
                    <measurement group_id="B3" value="389"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="114"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo</title>
        <description>Primary outcome is reported as the rate of type 1 diabetes per year among the primary stratum; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
        <time_frame>Metabolic and immunological tests were conducted every 6 months; participants were followed for a median of 2.7 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Insulin</title>
            <description>7.5 mg oral insulin capsules given before breakfast on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsule designed to mimic appearance of treatment capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Type 1 Diabetes Per Year Among Individuals in the Primary Stratum When Treated With Oral Inulin Versus Placebo</title>
          <description>Primary outcome is reported as the rate of type 1 diabetes per year among the primary stratum; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
          <units>Proportion with diabetes/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="203"/>
                <count group_id="O2" value="186"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.088" lower_limit="0.067" upper_limit="0.112"/>
                    <measurement group_id="O2" value="0.102" lower_limit="0.078" upper_limit="0.129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Type 1 Diabetes Per Year in Secondary Stratum (Stratum 2) When Treated With Oral Insulin Versus Placebo</title>
        <description>Secondary outcome is reported as the rate of type 1 diabetes per year among secondary stratum 2; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
        <time_frame>Metabolic and immunological tests were conducted every 6 months; participants were followed for a median of 2.7 years</time_frame>
        <population>Stratum 2: mIAA Confirmed, (ICA Confirmed) OR (ICA Not Confirmed AND ICA512+ AND GAD65ab+), low functioning beta cells</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Insulin</title>
            <description>7.5 mg oral insulin capsules given before breakfast on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsule designed to mimic appearance of treatment capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Type 1 Diabetes Per Year in Secondary Stratum (Stratum 2) When Treated With Oral Insulin Versus Placebo</title>
          <description>Secondary outcome is reported as the rate of type 1 diabetes per year among secondary stratum 2; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
          <population>Stratum 2: mIAA Confirmed, (ICA Confirmed) OR (ICA Not Confirmed AND ICA512+ AND GAD65ab+), low functioning beta cells</population>
          <units>Proportion with diabetes/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.181" lower_limit="0.096" upper_limit="0.291"/>
                    <measurement group_id="O2" value="0.341" lower_limit="0.206" upper_limit="0.511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Rate of Type 1 Diabetes in Secondary Stratum (Stratum 3+4) When Treated With Oral Insulin Versus Placebo</title>
        <description>Secondary outcome is reported as the rate of type 1 diabetes per year among secondary stratum 3+4; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
        <time_frame>Metabolic and immunological tests were conducted every 6 months; participants were followed for a median of 2.7 years</time_frame>
        <population>Combine stratum 3 (mIAA Confirmed, ICA Not Confirmed, ICA512+ OR GAD65ab+, high functioning beta cells) and stratum 4 (mIAA Confirmed, ICA Not Confirmed, ICA512+ OR GAD65ab+, low functioning beta cells)</population>
        <group_list>
          <group group_id="O1">
            <title>Oral Insulin</title>
            <description>7.5 mg oral insulin capsules given before breakfast on a daily basis.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo capsule designed to mimic appearance of treatment capsule</description>
          </group>
        </group_list>
        <measure>
          <title>Rate of Type 1 Diabetes in Secondary Stratum (Stratum 3+4) When Treated With Oral Insulin Versus Placebo</title>
          <description>Secondary outcome is reported as the rate of type 1 diabetes per year among secondary stratum 3+4; type 1 diabetes was diagnosed based on metabolic testing and assessment of symptoms. This is calculated by dividing the number of participants who develop diabetes by the total number of years of follow-up.</description>
          <population>Combine stratum 3 (mIAA Confirmed, ICA Not Confirmed, ICA512+ OR GAD65ab+, high functioning beta cells) and stratum 4 (mIAA Confirmed, ICA Not Confirmed, ICA512+ OR GAD65ab+, low functioning beta cells)</population>
          <units>Proportion with diabetes/year</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.051" lower_limit="0.026" upper_limit="0.086"/>
                    <measurement group_id="O2" value="0.047" lower_limit="0.022" upper_limit="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Oral Insulin</title>
          <description>7.5 mg oral insulin capsules given before breakfast on a daily basis.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo capsule designed to mimic appearance of treatment capsule</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="150" subjects_at_risk="283"/>
                <counts group_id="E2" subjects_affected="133" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="283"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <counts group_id="E1" events="30" subjects_affected="28" subjects_at_risk="283"/>
                <counts group_id="E2" events="34" subjects_affected="25" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy/Immunology</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="283"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="134" subjects_affected="67" subjects_at_risk="283"/>
                <counts group_id="E2" events="120" subjects_affected="62" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal/Soft Tissue</sub_title>
                <counts group_id="E1" events="45" subjects_affected="38" subjects_at_risk="283"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary/Upper Respiratory</sub_title>
                <counts group_id="E1" events="51" subjects_affected="30" subjects_at_risk="283"/>
                <counts group_id="E2" events="37" subjects_affected="30" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="283"/>
                <counts group_id="E2" events="20" subjects_affected="18" subjects_at_risk="277"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Carla Greenbaum</name_or_title>
      <organization>Benaroya Research Institute</organization>
      <email>cjgreen@benaroyaresearch.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

